Search

Your search keyword '"Thamlikitkul, V."' showing total 6 results
Start Over Author "Thamlikitkul, V." Publication Type Electronic Resources
6 results on '"Thamlikitkul, V."'

1. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition.

Author

Turnidge J., Thamlikitkul V., Thwaites G., Utili R., Webb S.A.R., Harris P.N.A., McNamara J.F., Paterson D.L., Lye D.C., Davis J.S., Tong S.Y.C., Bernard L., Cheng A.C., Doi Y., Fowler V.G., Kaye K.S., Leibovici L., Lipman J., Llewelyn M.J., Munoz-Price S., Paul M., Peleg A.Y., Rogers B.A., Rodriguez-Bano J., Seifert H., Turnidge J., Thamlikitkul V., Thwaites G., Utili R., Webb S.A.R., Harris P.N.A., McNamara J.F., Paterson D.L., Lye D.C., Davis J.S., Tong S.Y.C., Bernard L., Cheng A.C., Doi Y., Fowler V.G., Kaye K.S., Leibovici L., Lipman J., Llewelyn M.J., Munoz-Price S., Paul M., Peleg A.Y., Rogers B.A., Rodriguez-Bano J., and Seifert H.

Abstract

Objectives To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI). Methods Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. Results Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. Conclusions These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes.Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases

Published
2017

2. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition.

Author

Turnidge J., Thamlikitkul V., Thwaites G., Utili R., Webb S.A.R., Harris P.N.A., McNamara J.F., Paterson D.L., Lye D.C., Davis J.S., Tong S.Y.C., Bernard L., Cheng A.C., Doi Y., Fowler V.G., Kaye K.S., Leibovici L., Lipman J., Llewelyn M.J., Munoz-Price S., Paul M., Peleg A.Y., Rogers B.A., Rodriguez-Bano J., Seifert H., Turnidge J., Thamlikitkul V., Thwaites G., Utili R., Webb S.A.R., Harris P.N.A., McNamara J.F., Paterson D.L., Lye D.C., Davis J.S., Tong S.Y.C., Bernard L., Cheng A.C., Doi Y., Fowler V.G., Kaye K.S., Leibovici L., Lipman J., Llewelyn M.J., Munoz-Price S., Paul M., Peleg A.Y., Rogers B.A., Rodriguez-Bano J., and Seifert H.

Abstract

Objectives To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI). Methods Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. Results Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. Conclusions These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes.Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases

Published
2017

3. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Author

Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, L., Cheng, A. C., Doi, Y., Fowler, V. G., Jr., Kaye, K. S., Leibovici, L., Lipman, J., Llewelyn, M. J., Munoz-Price, S., Paul, M., Peleg, A. Y., Rodriguez-Bano, J., Rogers, B. A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., Paterson, D. L., Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, L., Cheng, A. C., Doi, Y., Fowler, V. G., Jr., Kaye, K. S., Leibovici, L., Lipman, J., Llewelyn, M. J., Munoz-Price, S., Paul, M., Peleg, A. Y., Rodriguez-Bano, J., Rogers, B. A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., and Paterson, D. L.

Abstract

Objectives: To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI). Methods: Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. Results: Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. Conclusions: These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Published
2017

4. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Author

Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, L., Cheng, A. C., Doi, Y., Fowler, V. G., Jr., Kaye, K. S., Leibovici, L., Lipman, J., Llewelyn, M. J., Munoz-Price, S., Paul, M., Peleg, A. Y., Rodriguez-Bano, J., Rogers, B. A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., Paterson, D. L., Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, L., Cheng, A. C., Doi, Y., Fowler, V. G., Jr., Kaye, K. S., Leibovici, L., Lipman, J., Llewelyn, M. J., Munoz-Price, S., Paul, M., Peleg, A. Y., Rodriguez-Bano, J., Rogers, B. A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., and Paterson, D. L.

Abstract

Objectives: To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI). Methods: Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. Results: Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. Conclusions: These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Published
2017

5. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Author

University of Queensland, National Institutes of Health (US), National Institute of Allergy and Infectious Diseases (US), National Health and Medical Research Council (Australia), German Center for Infection Research, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Red Española de Investigación en Patología Infecciosa, Innovative Medicines Initiative, Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, Louis, Cheng, A. C., Doi, Y., Fowler, Vance G., Kaye, K. S., Leibovici, Leonard, Lipman, Jeffrey, Llewelyn, Martin J., Muñoz-Price, S., Paul, Mical, Peleg, A. Y., Rodríguez-Baño, Jesús, Rogers, B. A., Seifert, Harald, Thamlikitkul, V., Thwaites, Guy, Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., Paterson, David L., University of Queensland, National Institutes of Health (US), National Institute of Allergy and Infectious Diseases (US), National Health and Medical Research Council (Australia), German Center for Infection Research, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Red Española de Investigación en Patología Infecciosa, Innovative Medicines Initiative, Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, Louis, Cheng, A. C., Doi, Y., Fowler, Vance G., Kaye, K. S., Leibovici, Leonard, Lipman, Jeffrey, Llewelyn, Martin J., Muñoz-Price, S., Paul, Mical, Peleg, A. Y., Rodríguez-Baño, Jesús, Rogers, B. A., Seifert, Harald, Thamlikitkul, V., Thwaites, Guy, Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., and Paterson, David L.

Abstract

[Objectives] To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI)., [Methods] Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process., [Results] Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed., [Conclusions] These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes.

Published
2017

6. Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii

Author

Maifiah, MHM, Cheah, S-E, Johnson, MD, Han, M-L, Boyce, JD, Thamlikitkul, V, Forrest, A, Kaye, KS, Hertzog, P, Purcell, AW, Song, J, Velkov, T, Creek, DJ, Li, J, Maifiah, MHM, Cheah, S-E, Johnson, MD, Han, M-L, Boyce, JD, Thamlikitkul, V, Forrest, A, Kaye, KS, Hertzog, P, Purcell, AW, Song, J, Velkov, T, Creek, DJ, and Li, J

Abstract

Multidrug-resistant Acinetobacter baumannii presents a global medical crisis and polymyxins are used as the last-line therapy. This study aimed to identify metabolic differences between polymyxin-susceptible and polymyxin-resistant A. baumannii using untargeted metabolomics. The metabolome of each A. baumannii strain was measured using liquid chromatography-mass spectrometry. Multivariate and univariate statistics and pathway analyses were employed to elucidate metabolic differences between the polymyxin-susceptible and -resistant A. baumannii strains. Significant differences were identified between the metabolic profiles of the polymyxin-susceptible and -resistant A. baumannii strains. The lipopolysaccharide (LPS) deficient, polymyxin-resistant 19606R showed perturbation in specific amino acid and carbohydrate metabolites, particularly pentose phosphate pathway (PPP) and tricarboxylic acid (TCA) cycle intermediates. Levels of nucleotides were lower in the LPS-deficient 19606R. Furthermore, 19606R exhibited a shift in its glycerophospholipid profile towards increased abundance of short-chain lipids compared to the parent polymyxin-susceptible ATCC 19606. In contrast, in a pair of clinical isolates 03-149.1 (polymyxin-susceptible) and 03-149.2 (polymyxin-resistant, due to modification of lipid A), minor metabolic differences were identified. Notably, peptidoglycan biosynthesis metabolites were significantly depleted in both of the aforementioned polymyxin-resistant strains. This is the first comparative untargeted metabolomics study to show substantial differences in the metabolic profiles of the polymyxin-susceptible and -resistant A. baumannii.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results